These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect on blood coagulation and fibrinolysis in women using norethisterone or a combination of ethinyloestradiol and quingestianol.
    Author: Korsan-Bengtsen K, Larsson B.
    Journal: Gynecol Obstet Invest; 1978; 9(6):312-8. PubMed ID: 754993.
    Abstract:
    Oral contraceptives of the combined type and contraceptives containing only progestagen were studied for their effect on blood coagulation and fibrinolysis. Several blood parameters were determined in 13 women before and during the 3rd month of use of either 0.3 mg norethisterone alone or 0.05 mg ethinyloestradiol combined with 0.5 mg quingestianol. Blood samples were obtained on days 2--4, 9--11, 16--18 and 23--25 of the menstrual cycle. Except on days 16--18, a significantly increased fibrinolytic activity and a significantly increased variation in plasminogen were observed in women using the combined type of contraceptives, but not in the women using contraceptives containing only norethisterone. The other variables studied were not significantly changed, which might be due to the doses and types of progestagens used in the present series. Both combined and progestagen-only oral contraceptives (OCs) were studied for their effects on blood coagulation and fibrinolysis. The preparations given to 6/13 subjects was Mini-Pe (.3 mg of nrethisterone) and to 7/13 piloval (.5 mg of ethinyl estradiol and .5 mg of quingestanol acetate). The Mini-Pe was given in continuous dosages, whereas Piloval was given cyclically. Various blood parameters were tested. Only 2 significant differences were noted during treatment: 1) significantly higher (P .05) variation of plasminogen during Piloval treatment. No such differences were noted during the control period. The fibrinolytic activity was significantly higher on all occasions, except Days 16-18 during treatment with Piloval, than during control period. No other significant differences between treatment and control periods were found. The control period was before OC use was started.
    [Abstract] [Full Text] [Related] [New Search]